Hofseth BioCare ASA: Private placement successfully placed

Core Viewpoint - Hofseth BioCare ASA ("HBC") is conducting a private placement of new shares to raise capital for growth, balance sheet strengthening, and general corporate purposes, with a total size of approximately NOK 158 million from the issuance of 87,811,110 shares at NOK 1.80 each [2][3][4]. Group 1: Private Placement Details - The private placement consists of two tranches: Tranche 1 will raise NOK 106.5 million, while Tranche 2 will raise NOK 28.67 million, with the total expected proceeds being between NOK 155 million and NOK 181 million [2][4]. - The share capital increase will be executed through the issuance of 59,144,444 shares with a par value of NOK 0.01, and the first trading day for Tranche 1 shares is expected on or about 29 October 2025 [4][6]. - The completion of the private placement is contingent upon the registration of the share capital increase and the satisfaction of specific conditions related to the divestment of shares in AecorBio [5]. Group 2: Investor Participation - Major investors include Guy Urquhart, who subscribed for 55,444,444 shares for approximately NOK 100 million, and Hofseth International AS, which subscribed for 28,666,666 shares for about NOK 52 million [7]. - Shareholders representing 68.2% of the outstanding shares have committed to vote in favor of the share capital increase for Tranche 2 [6]. Group 3: Subsequent Offering - A subsequent offering of up to 16,666,666 new shares may be conducted, aimed at existing shareholders who did not participate in the private placement, potentially raising an additional NOK 30 million [9]. - The subsequent offering is subject to corporate approvals and market conditions, and any remaining shares may be allocated to strategic investors at the Board's discretion [9]. Group 4: Compliance and Structure - The Board of Directors has ensured that the private placement complies with Norwegian laws regarding equal treatment of shareholders and has structured the transaction to minimize completion risks compared to a rights issue [8]. - The proposed private placement is considered to be in the common interest of the company and its shareholders, despite deviations from shareholders' preferential rights [8].